

10 Διεπιστημονικό Συνέδριο

# ΠΡΩΙΜΟΣ και τοπικά προχωρημένος ΚΑΡΚΙΝΟΣ

Θεραπευτικές Εξελίξεις  
& Διλήμματα

20-21  
Μαΐου  
2022

Πολυχώρος  
ΤΙΤΑΝΙΑ  
Σπέτσες

ΘΑ ΧΟΡΗΓΗΣΟΥΝ  
ΜΟΡΙΑ  
ΣΥΝΕΧΙΖΟΜΕΝΗΣ  
ΙΑΤΡΙΚΗΣ  
ΕΚΠΑΙΔΕΥΣΗΣ  
(CME-CPD)

ΟΡΓΑΝΩΣΗ

ΑΙΓΙΔΑ

ΣΥΝΕΡΓΑΣΙΕΣ

ΓΡΑΜΜΑΤΕΙΑ ΣΥΝΕΔΡΙΟΥ



Β' Παθολογική - Ογκολογική Κλινική  
Δ.Θ.Κ.Α. «ΥΓΕΙΑ»





Τηλ.: 210 6897552-3  
Φαξ: 210 6897555  
E-mail: info@gk.gr  
Site: www.gk.gr

ενδείξεις για επικουρική  
ακτινοθεραπεία στα πρώιμα  
στάδια ΜΜΚΠ  
- ρόλος της ακτινοθεραπείας  
στο χειρουργηθέν ΙΙΙΑ Ν2  
στάδιο



Ιωάννης Γεωργακόπουλος  
Ακτινοθεραπευτής Ογκολόγος

# επιδημιολογία


## Estimated New Cases

			Males	Females			
Prostate	248,530	26%			Breast	281,550	30%
Lung & bronchus	119,100	12%			Lung & bronchus	116,660	13%
Colon & rectum	79,520	8%			Colon & rectum	69,980	8%
Urinary bladder	64,280	7%			Uterine corpus	66,570	7%
Melanoma of the skin	62,260	6%			Melanoma of the skin	43,850	5%
Kidney & renal pelvis	48,780	5%			Non-Hodgkin lymphoma	35,930	4%
Non-Hodgkin lymphoma	45,630	5%			Thyroid	32,130	3%
Oral cavity & pharynx	38,800	4%			Pancreas	28,480	3%
Leukemia	35,530	4%			Kidney & renal pelvis	27,300	3%
Pancreas	31,950	3%			Leukemia	25,560	3%
<b>All Sites</b>	<b>970,250</b>	<b>100%</b>	<b>All Sites</b>	<b>927,910</b>	<b>100%</b>		

## Estimated Deaths

			Males	Females			
Lung & bronchus	69,410	22%			Lung & bronchus	62,470	22%
Prostate	34,130	11%			Breast	43,600	15%
Colon & rectum	28,520	9%			Colon & rectum	24,460	8%
Pancreas	25,270	8%			Pancreas	22,950	8%
Liver & intrahepatic bile duct	20,300	6%			Ovary	22,950	5%
Leukemia	13,900	4%			Uterine corpus	12,940	4%
Esophagus	12,410	4%			Liver & intrahepatic bile duct	9,930	3%
Urinary bladder	12,260	4%			Leukemia	9,760	3%
Non-Hodgkin lymphoma	12,170	4%			Non-Hodgkin lymphoma	8,550	3%
Brain & other nervous system	10,500	3%			Brain & other nervous system	8,100	3%
<b>All Sites</b>	<b>319,420</b>	<b>100%</b>	<b>All Sites</b>	<b>289,150</b>	<b>100%</b>		


# επιδημιολογία



role of adjuvant RT



# adjuvant RT in completely resected NSCLC

## PORT Metaanalysis of RCTs




# adjuvant RT in NSCLC

## PORT Metaanalysis of RCTs




# adjuvant RT in NSCLC

## PORT Metaanalysis of RCTs



# adjuvant RT in NSCLC

## PORT Metaanalysis of RCTs






# adjuvant RT in NSCLC

## updated PORT Metaanalysis of RCTs

	(no. events/no. entered)	
	S + RT	S
Belgium	88/98	80/104
LCSG 773	84/110	81/120
CAMS	83/153	100/164
Lille	59/81	45/82
EORTC 08861	26/52	20/54
MRC LU11	116/154	123/154
GETCB 04CB86	69/99	59/90
Slovenia	30/35	33/39
GETCB 05CB88	152/274	120/265
Italy (3)	23/51	30/53
<b>Total</b>	<b>730/1107</b>	<b>691/1125</b>



# adjuvant RT in NSCLC guidelines

- early stage

R1 – R2 resection

upstaged surgically to pN2

- locally advanced

stage IIIA pN2